ClinicalTrials.gg
RecruitingNCT03994874PUREUpdated May 16, 2025

Peritoneal Ultrafiltration in Cardio Renal Syndrome.

A Phase 1/2 interventional study of PolyCore (Polydextrin, L-Carnitine, D-xylitol) in Congestive Heart Failure, sponsored by Iperboreal Pharma Srl. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Iperboreal Pharma Srl · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 449 studies in Heart Failure with a site in Italy — 110 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.

Planned enrollment
201st of 292
84 · median 200
Started
2025
with 25 others
Phase 1/2
2 of 449
1 open now
Primary completion
2026-12
later than 54 of 129 live
Registered
261st of 449
by date

Among the 449 studies in Heart Failure with a site in Italy, this one is the 201st largest by planned enrollment of the 292 interventional ones that give a count, is one of 26 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 54 of the 129 other live ones, and was the 261st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

110 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:

105 more — sign in →

All 110 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 449 studies in Heart Failure with a site in Italy, or all of them as a file.
02

Study summary

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

Read the detailed description

The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 yrs
  • ≤60%
  • Classification of III-IV despite guidelines directed medical therapy
  • Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (≥ moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio ≥0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg/kg/day), coupled with urinary sodium excretion ≤ mEq/L, confirmatory of loop diuretic resistance.
  • Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse \<50% or absent due to intravascular fluid overload)
  • Decreased kidney function addressed by the measurement of (GFR) urea clearance + /2 (>15 ml/min/1,73 m2)
  • NT pro-BNP plasma concentration > 1000 pg/ml or BNP plasma concentration > 250 pg/ml
  • at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment
  • An appropriate PUF technique candidate.
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Recipients of heart transplantation
  • Presence of a mechanical circulatory support device;
  • Hypertrophic obstructive cardiomyopathy;
  • Uncontrolled hypertension with systolic blood pressure ≥ 160 mmHg
  • Severe valvular stenosis;
  • Restrictive cardiomyopathy;
  • Acute coronary syndrome ≤ 6 months before;
  • Active myocarditis
  • Cardiosurgical or Endo-radiological heart procedures ≤ 6 months before
  • Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT ≤ 6 months before;
  • Patient with end-stage renal disease, urea clearance + /2 (\<15 ml/min/1,73 m2 GFR)
  • Any major organ transplant (liver, lung, kidney)
  • Lung embolism ≤ 6 months before;
  • Fibrotic lung disease;
  • Liver Cirrhosis;
  • Absolute to peritoneal catheter implantation;
  • Logistical and or organizational contra-indication to treatment
  • Active ;
  • Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later
  • Female patients of childbearing age who do not use adequate contracteption.
  • Unwilling and unable to give ;
  • Enrolment in another clinical trial involving medical or device based interventions.
  • Hypersensibility to IMP components.
  • Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    PolyCore PUF

    PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.

    Drug: PolyCore (Polydextrin, L-Carnitine, D-xylitol)

  • No intervention
    Control

    Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.

Interventions

  • DrugPolyCore (Polydextrin, L-Carnitine, D-xylitol)

    A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.

    Also known as: PolyCore peritoneal dialysis solution

06

What researchers measure

Primary outcomes

  1. Composite end-point of mortality and worsening patient's condition

    * patient's mortality - or * the need of increasing of ≥50% the initial daily dose of loop diuretic - or * the hospitalization for infusional therapy with loop diuretic based on the lack of adequate response to maximal dose of oral furosemide (\>2.5 mg/kg/day) - or * requiring other methods of treatment \[i.e. PUF or hemodialysis\], based on persistence of high venous congestion (detected with central venous pressure measurement: \>8 mm Hg or dilated inferior cava vein, without respiratory change, measured with focused abdominal echography, and coupled with body weight increase of 1 kg or more in the last 24 hrs.

    Time frame: Up to 7 months from randomization

Secondary outcomes

  1. 6 min Walking distance

    Change from the baseline

    Time frame: At 3, 6 and 7 months from randomization

  2. Quality of life tested with Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Change from the baseline

    Time frame: At 3, 6 and 7 months from randomization

  3. Number of patients with decrease of NT pro-BNP (N-terminal pro brain natriuretic peptide)

    The number of patients with a decrease in NT pro-BNP level of ≥25% from baseline

    Time frame: At 3, 6 and 7 months from randomization

  4. Worsening of renal function

    Estimated Glomerular Filtration Rate (eGFR) ≤20 ml/min

    Time frame: Up to 7 months from randomization

  5. Cumulative daily dosage of loop diuretic

    Change over the 6 months of study treatment,

    Time frame: Up to 7 months from randomization

  6. Use of hospital resources

    The number of days spent in-hospital because of HF exacerbation during the 6 months of study treatment

    Time frame: Up to 7 months from randomization

  7. New York Heart Association (NYHA) class

    Change from baseline

    Time frame: At 3, 6 and 7 months from randomization and during long-term FUs

  8. Number of patients requiring hospitalization

    Hospitalization for infusional therapy with loop diuretic

    Time frame: Up to 7 months from randomization

  9. Number of patients increasing of ≥50% the initial daily dose of loop diuretic

    Change from baseline

    Time frame: Up to 7 months from randomization

  10. Adverse Events

    Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory or instrumental test, will be collected, recorded and followed as appropriate.

    Time frame: through study completion, an average of 1 year

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2019
First posted
Jun 21, 2019
StartActual
Apr 16, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03994874
Lead sponsor
Iperboreal Pharma Srl
Responsible party
Sponsor
First posted
Jun 21, 2019
Start date
Apr 16, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 16, 2025

Study contacts

Arduino Arduini, MD
Contact
a.arduini@corequest.ch
+41 79 7878312
Edoardo Gronda, MD
study director · Policlinico Milano - on behalf of Cardio Renal and Metabolism Working Group of the ANMCO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion